Oxford Immunotec beat analysts' consensus estimates on the top and bottom lines as its second quarter net loss last year swung to a profit this year.
UK researchers said they are developing a commercial test that could enable sensitive detection of tuberculosis DNA in blood and provide an option to broaden screening.
The program started in 2014, originally to increase access to HIV diagnostics, and provides special pricing to qualifying organizations in eligible countries.
The project, called Seq&Treat, will be implemented in Brazil, China, Georgia, India, and South Africa starting in October.
Rapid Biosensor Systems said its point-of-care pre-production breath system has achieved high performance during TB field testing in Ethiopia and India.
The anticipated shortage for clinics comes at a time when more clinicians are already switching to lab-based IGRA testing, diagnostic industry executives said.
The test, called Fujifilm SILVAMP TB LAM, was found to be about 30 percent more sensitive than the Alere Determine TB LAM Ag test from Abbott.
Oxford Immunotec said that it expects the report to further the trend toward interferon-gamma release assay adoption for healthcare personnel screening.
The company logged total Q1 revenues of $14.8 million, above its previous guidance of a revenue range of $13.4 million to $14.1 million.
Based on PCR technology acquired from Hain Diagnostics, the test and platform enable rapid detection of TB, as well as assessment of antibiotic resistance.